Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMAGONA trial of semaglutide and testosterone undecanoate in men with obesity-associated functional hypogonadism
2026-527373-11-00Phase 2Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide and testosterone undecanoate in functional hypogonadism (FHH) and obesity (4 arms), sponsored by Capital Region of Denmark. Primary endpoint: Difference in fat free mass percentage. Planned start Sep 2026; status: authorised.
02
Drugs
semaglutidetestosterone undecanoate
03
Conditions
functional hypogonadism (FHH)obesity
Beyond the preview
Go deeper on 2026-527373-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527373-11-00.